Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.34 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | STAT5B | P51692 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177046 | 0.97 | L3MBTL1 (0.32) | L3MBTL1F2 | |
| SCHEMBL6178236 | 0.84 | L3MBTL1 (0.35) | L3MBTL1F2CA14 | |
| SCHEMBL6965307 | 0.77 | L3MBTL1 (0.32) | L3MBTL1MMP13 | |
| SCHEMBL6174342 | 0.73 | ITGB3 (0.45) | L3MBTL1 | |
| SCHEMBL28643624 | 0.73 | F2 (0.52) | L3MBTL1F2CA12CA1CA7 | |
| SCHEMBL2797220 | 0.72 | HDAC3 (0.47) | L3MBTL1CA12CA1CA7CA14 | |
| SCHEMBL6421398 | 0.71 | ITGB3 (0.41) | F2 | |
| SCHEMBL25048209 | 0.70 | RCE1 (0.44) | L3MBTL1CA12CA1CA7CA14 | |
| SCHEMBL381079 | 0.69 | KDM4E (0.44) | L3MBTL1CA12CA1CA7CA14 | |
| SCHEMBL31583919 | 0.68 | CA14 (0.44) | L3MBTL1CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | L3MBTL1 4796/4885F2 2061/4885CA12 2412/4885 |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | L3MBTL1 4658/4885F2 1452/4885CA12 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.